In The Eye Of The Storm? Merck’s Quarter Is Bright, But Vioxx Cloud Looms

Efforts to reinvigorate Merck's pipeline, cut costs and restore earnings growth paid off in the first quarter as the drug maker reignited investor enthusiasm